Browse 60 Peritoneal Carcinomatosis Medical Studies Across 242 Cities
10 Phase 3 Trial · 670 Peritoneal Carcinomatosis Clinics
What are Peritoneal Carcinomatosis Clinical Trials?
Peritoneal carcinomatosis (PC) is a rare cancer affecting the peritoneum, the thin membrane enveloping the abdominal organs. There are two types of PC: primary and secondary.
Primary peritoneal carcinomatosis (PPC) is seen in women at a higher risk for ovarian cancer. The reason for this is unknown and recent research shows that women can still develop PPC after their ovaries have been removed. In 75% of cases of ovarian cancer, peritoneal carcinomatosis is seen.
Secondary peritoneal carcinomatosis develops as other abdominal growths spread to the peritoneum, leading to new growths. Due to this, PC is generally considered a sign of advanced abdominal cancer. There are no symptoms for the early stages of PC, but some cases have reported general symptoms such as diarrhea, constipation, bloating and frequent urination, which often leads to misdiagnosis.
Why Is Peritoneal Carcinomatosis Being Studied Through Clinical Trials?
Peritoneal carcinomatosis (PC) is asymptomatic in its early stages, making it very challenging to detect and study. Estimates suggest it develops in 1 in every 3,300,000. In the cases of primary peritoneal carcinomatosis (PPC), researchers believe that as many as 15% of women diagnosed with ovarian cancer actually have PPC.
Clinical trials are essential to developing better early detection methods before the peritoneum has been wholly affected in both primary and secondary cases. As peritoneal carcinomatosis is linked to other cancers that develop in the abdominal cavity, its treatment is closely linked to cancer treatment trials.
What Treatment is Available for Peritoneal Carcinomatosis?
Peritoneal carcinomatosis (PC) can be confirmed in several ways. Blood tests and biopsies measure the amounts of particular antibody markers that signal cancerous growth. CT scans and MRIs are also done. These scans show the otherwise smooth peritoneum as grainy and bumpy.
As peritoneal carcinomatosis is often diagnosed during the late stages of other abdominal cancers, it is tough to treat. PC is unresponsive to chemotherapy, so most doctors focus on managing symptoms and pain instead.
However, if PC is detected earlier, a few treatment options are available, and they are commonly done together.
What are Some Recent Peritoneal Carcinomatosis Clinical Trial Breakthroughs?
2009: This study suggests that hyperthermic intraperitoneal chemotherapy (HIPEC) can help increase the 5-year survival rate from 15% to 50%. More research is necessary to verify these results.
2016: This study suggests that patients who have had a salpingo-oophorectomy or oophorectomy can still develop primary peritoneal carcinomatosis (PPC), concluding that follow-ups and long-term healthcare are necessary to prevent the development of PPC.